Download PDF
Dtsch Med Wochenschr 2013; 138(34/35): 1734-1737
DOI: 10.1055/s-0033-1343340
Kommentar | Commentary
Immunologie, Impfmedizin
© Georg Thieme Verlag KG Stuttgart · New York

Pneumokokkenimpfung

Stellungnahme eines ExpertenPneumococcal vaccineAn expert‘s statement
M. W. Pletz
1   Zentrum für Infektionsmedizin und Krankenhaushygiene, Integriertes Forschungs- und Behandlungszentrum (IFB) Sepsis und Sepsisfolgen (CSCC), Universitätsklinikum Jena
› Author Affiliations
Further Information

Publication History

22 April 2013

02 May 2013

Publication Date:
09 August 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Pneumokokken - Vakzine

Keywords

pneumococcus - vaccination
 

  • Literatur

  • 1 (ACIP) ACoIP. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Am J Transplant 2013; 13: 232-235
    CrossrefPubMedGoogle Scholar
  • 2 Bogaert D, van Belkum A, Sluijter M et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004; 363: 1871-1872
    CrossrefPubMedGoogle Scholar
  • 3 Christenson B, Lundbergh P, Hedlund J et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001; 357: 1008-1011
    CrossrefPubMedGoogle Scholar
  • 4 Clutterbuck EA, Lazarus R, Yu LM et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205: 1408-1416
    CrossrefPubMedGoogle Scholar
  • 5 Dagan R, Melamed R, Muallem M et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174: 1271-1278
    CrossrefPubMedGoogle Scholar
  • 6 de Roux A, Schmole-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 1015-1023
    CrossrefPubMedGoogle Scholar
  • 7 Elemraid MA, Rushton SP, Shirley MD et al. Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia. Epidemiol Infect 2012; DOI: DOI: 10.1017/S0950268812002257. 1-8
    PubMedGoogle Scholar
  • 8 Engel C, Brunkhorst FM, Bone HG et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007; 33: 606-618
    CrossrefPubMedGoogle Scholar
  • 9 Hak E, Grobbee DE, Sanders EA et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66: 378-383
    PubMedGoogle Scholar
  • 10 Kuhlmann A, Theidel U, Pletz M et al. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Economics Review 2012; 2: 4
    CrossrefPubMedGoogle Scholar
  • 11 Kwetkat A, Hagel S, Pletz MW. Impfungen im Alter. Der Pneumologe 2012; 9: 1-7
    PubMedGoogle Scholar
  • 12 Lazarus R, Clutterbuck E, Yu LM et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011; 52: 736-742
    CrossrefPubMedGoogle Scholar
  • 13 Leal J, Vanderkooi OG, Church DL et al. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta. Pediatr Infect Dis J 2012; 31: e169-175
    PubMedGoogle Scholar
  • 14 Moberley SA, Holden J, Tatham DP et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; DOI: DOI: 10.1002/14651858.CD000422.pub2. CD000422
    PubMedGoogle Scholar
  • 15 Musher DM, Manoff SB, McFetridge RD et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7: 919-928
    CrossrefPubMedGoogle Scholar
  • 16 WHO. 23-Valent pneumococcal polysaccharide vaccine: WHO position paper. Wkly Epidemiol Rec 2008; 83: 373-384
    PubMedGoogle Scholar
  • 17 Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41
    CrossrefPubMedGoogle Scholar
  • 18 Pletz MW, Ewig S, Höffken G. Stellungnahme von Experten der PEG. Chemother J 2012; 21: 109-112
    PubMedGoogle Scholar
  • 19 Pletz MW, Maus U, Hohlfeld JM et al. Pneumokokkenimpfung: Konjugatimpfstoff induziert Herdenimmunitat und reduziert Antibiotikaresistenz. Dtsch Med Wochenschr 2008; 133: 358-362
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Pletz MW, van der Linden M, Fobiwe JP et al. Pneumokokkenimpfung bei Erwachsenen – Hintergrunde der aktuellen Diskussion. Dtsch Med Wochenschr 2013; 138: 185-187
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Schnoor M, Hedicke J, Dalhoff K et al. Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect 2007; 55: 233-239
    CrossrefPubMedGoogle Scholar
  • 22 STIKO. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2009. 2009: 30
    Google Scholar
  • 23 STIKO. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut / Stand: Juli 2011. Epidemiologisches Bulletin 2011; Nr. 30: 275-294
    PubMedGoogle Scholar
  • 24 STIKO. Stellungnahme zur Impfung Erwachsener gegen Pneumokokken. Epidemiologisches Bulletin 2012; DOI: 55-56
    PubMedGoogle Scholar
  • 25 Tessmer A, Welte T, Schmidt-Ott R et al. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J 2011; 38: 147-153
    CrossrefPubMedGoogle Scholar
  • 26 Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-79
    CrossrefPubMedGoogle Scholar
  • 27 Robert Koch-Institut. PneumoWeb. Laborsentinel invasiver Pneumokoken-Erkrankungen. http://www.rki.de/DE/Content/Infekt/Sentinel/Pneumoweb/Monatsstatistik.html?nn=2378874#doc2378878bodyText2 Letzter Zugriff: 27.06.2013
    Google Scholar